Acadia Climbs 150% on $395M Pimavanserin Deal with Biovail
Shares of Acadia Pharmaceuticals Inc. gained 150 percent in midday trading on Monday after the company unveiled a surprise partnership with Biovail Corp. for North American rights to its lead drug, pimavanserin. The deal may bring Acadia $30 million up front and $365 million in milestone [...]